
    
      A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the
      Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg with Anastrozole (ARIMIDEX) 1 mg
      as Hormonal Treatment for Postmenopausal Women with Hormone Receptor-Positive Locally
      Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal
      Therapy.
    
  